Objetivo: Evaluar la seguridad y eficacia de la biopsia guiada cognitivamente (BGC) con la resonancia magnética multiparamétrica para obtener muestras del nódulo dominante sospechoso de cáncer de próstata.
Material y métodos: Realizamos una BGC en 24 pacientes tras hacer una RM. Todos los pacientes firmaron el consentimiento informado. Las biopsias se realizaron por vía transrectal con control ecográfico. Las 12 primeras muestras se obtuvieron con el protocolo realizado en el CHMH, posteriormente se realizó una muestra más de la lesión diana determinada por la RM. El anatomopatólogo valoró los 12 cilindros y la muestra.
Resultados: se diagnosticaron De los 24 pacientes a los que se les realizo la RM y posteriormente la biopsia, a uno de ellos no se le realizo biopsia dirigida a nódulo dominante puesto que no se identificó alguno. De las 23 muestras restantes 20 (87%) fueron reportadas por el servicio de patología como Adenocarcinoma, 1(4%) como prostatitis y 2(5%) como HPN. De las 20 muestras reportadas como Adenocarcinoma 2 (10%) fueron clasificadas con una escala de Gleson 4, 8 (40%) muestras con una escala de Gleson 7, 6(30%) muestras con escala de Gleson 8 y 4 ( 20%) muestras con escala de Gleson 9.De las 23 muestras P que fueron reportadas por patología 20(83%) muestras fueron reportadas como Adenocarcinoma y 3(17%) con otro diagnóstico.
Objective: To assess the safety and efficacy of cognitive-guided biopsy (BGC) with multiparametric magnetic resonance imaging to obtain samples of the dominant nodule suspected of prostate cancer.
Material and methods: We performed BGC in 24 patients after an MRI. All patients signed informed consent. Biopsies were performed transrectal with ultrasound control. The first 12 samples were obtained with the protocol performed in the CHMH, after which a further sample of the target lesion determined by the MRI was performed. The pathologist evaluated the 12 cylinders and the sample.
Results: were diagnosed Of the 24 patients who underwent MRI and then biopsy, one of them did not undergo a biopsy directed to a dominant nodule since no one was identified. Of the 23 remaining samples, 20 (87%) were reported by the pathology service as Adenocarcinoma, 1 (4%) as prostatitis and 2 (5%) as NPH. Of the 20 samples reported as Adenocarcinoma 2 (10%) were classified with a scale of Gleson 4, 8 (40%) samples with a scale of Gleson 7, 6 (30%) samples with scale of Gleson 8 and 4 (20% ) Samples with Gleson scale 9. Of the 23 P samples that were reported for pathology 20 (83%) samples were reported as Adenocarcinoma and 3 (17%) with another diagnosis
